Table 1.
Characteristics of included studies investigating periprocedural antiplatelet use in patients with ischemic stroke who underwent acute MT.
| Study characteristics | Population characteristics | Recanalization therapy | Study treatment and contrast | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reference | Study design | N | Age | NIHSS score at baseline | Occlusion location | IV tPA, n/N (%) | IA tPA,n/N (%) | MT, n/N (%) | Time from symptom onset to recanalization therapy (min) | Antithrombotic treatment | Indication for antithrombotic treatment | Time from symptom onset to antithrombotic treatmenta | Treatment, n/N (%) | Control | Control, n/N (%) |
| Broeg-Morvay et al.a (22) | Prospective cohort | 231b | Meanc: 69 (± 14) | Medianc: 15 (2–37) | Anterior + posterior circulation | 231/231 (100%) | 69/231 (30%) | 212/231 (92%) | Meanc: 270 (±83) | ASA loading dose (median: 300 mg) | Prevention of re-occlusion Stenting | Acute | 50/231 (22%) | No ASA | 181/231 (78%) |
| Ernst et al. (24) | Retrospective cohort | 54b | Mean: 65 | Median: 32 | Posterior circulation | 0/54 (0%) | 54/54 (100%) | 31/54 (57%) | Median: 198 | IV abciximab bolus (0.25 mg/kg) followed by continuous infusion, or, tirofiban bolus (10 μg/kg) followed by continuous infusion | Protocol-based care | Acute | 54/54 (100%) | NR | NR |
| Memon et al. (31) | Prospective cohort | 35b | Mean: 62 | Median: 13 (5–22) | NR | 2/35 (6%) | 12/35 (34%) | ≥20/35 (≥57%) | Median: 230 | IA eptifibatide bolus (180 μg/kg) | Presence of distal emboli Inaccessible location by MT Prevention of re-occlusion |
Acute | 35/35 (100%) | NR | NR |
| Mulder et al. (32) | Post hoc analysis on phase III RCT | 233 | Median: 66 (55–76) | Median: 17 (14–21) | Anterior circulation | 203/233 (87%) | 24/233 (10%) | 233/233 (100%) | Median: 260 (210–313) | Any antiplatelet use (single and dual) | Comorbidity | Prior use | 64/233 (27%) | No antiplatelet use | 169/233 (73%) |
| Pandhi et al. (39) | Retrospective cohort | 217 | Meanc: 60 (±14) | Medianc: 16 (12–21) | Anterior + posterior circulation | 141/217 (65%) | 0/217 (0%) | 217/217 (100%) | Mean: 361 | Any antiplatelet use (single and dual) | Comorbidity | Prior use | 71/217 | No antiplatelet use | 146/217 (67%) |
| Sugiura et al. (36) | Prospective cohort | 204b | Mean: 71 (± 13) | Median: 18 (13–22) | Anterior + posterior circulation | 80/204 (39%) | 42/204 (21%) | 170/204 (83%) | Mean: 188 (±101) | Any antiplatelet use (single and dual) | Comorbidity | Prior use | 48/204 (24%) | No antiplatelet use | 156/204 (76%) |
Characteristics of the included studies are presented by sample size (percentage), means (SDs), medians (interquartile ranges), or by remarks.
ASA, acetylsalicylic acid; IA, intraarterial; IV, intravenous; MT, mechanical thrombectomy (by means of stent retriever or aspiration); NIHSS, National Institutes of Health Stroke Scale; NR, not reported; RCT, randomized controlled trial; tPA, tissue plasminogen activator.
aTime from symptom onset to antithrombotic treatment was divided into acute treatment administration (<6 h) and early administration (6–24 h).
bNot solely MT.
cExtracted data from the subgroup that received antiplatelet agents.